D A Peura

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials
    David A Peura
    Emeritus Professor, University of Virginia School of Medicine, Charlottesville, VA
    Postgrad Med 126:33-41. 2014
  2. ncbi request reprint Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction
    David A Peura
    University of Virginia Health System, Charlottesville, V 22908 0708, USA
    Aliment Pharmacol Ther 22:1. 2005
  3. ncbi request reprint Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine
    David A Peura
    University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    Dig Dis Sci 54:955-63. 2009
  4. ncbi request reprint Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects
    D A Peura
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, VA 22908 0708, USA
    Aliment Pharmacol Ther 30:459-68. 2009
  5. ncbi request reprint Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients
    David A Peura
    University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 44:180-5. 2010
  6. ncbi request reprint Chairmen's summary: dichotomies and directions in acid-related disorders
    D A Peura
    University of Virginia, Health Sciences Center, Charlottesville, VA, USA
    Aliment Pharmacol Ther 19:77-80. 2004
  7. ncbi request reprint Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience
    D A Peura
    University of Virginia Health Sciences Center, Charlottesville, VA, USA
    Aliment Pharmacol Ther 30:1010-21. 2009
  8. ncbi request reprint Proton pump inhibitors: effective first-line treatment for management of dyspepsia
    David A Peura
    University of Virginia Health Sciences Center, Charlottesville, VA 22908 0708, USA
    Dig Dis Sci 52:983-7. 2007
  9. ncbi request reprint Practical advice on eradicating Helicobacter pylori infection
    D Y Graham
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 105:137-40, 145-8. 1999
  10. ncbi request reprint Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis
    D Y Graham
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 105:113-6, 121-3, 127-8 passim. 1999

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials
    David A Peura
    Emeritus Professor, University of Virginia School of Medicine, Charlottesville, VA
    Postgrad Med 126:33-41. 2014
    ..To determine the efficacy of a 14-day regimen of esomeprazole 20 mg for the treatment of frequent heartburn in subjects who are likely to self-treat with over-the-counter medications without consulting a health care provider...
  2. ncbi request reprint Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction
    David A Peura
    University of Virginia Health System, Charlottesville, V 22908 0708, USA
    Aliment Pharmacol Ther 22:1. 2005
  3. ncbi request reprint Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine
    David A Peura
    University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    Dig Dis Sci 54:955-63. 2009
    ..Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief...
  4. ncbi request reprint Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects
    D A Peura
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, VA 22908 0708, USA
    Aliment Pharmacol Ther 30:459-68. 2009
    ..Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms...
  5. ncbi request reprint Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients
    David A Peura
    University of Virginia Health System, Charlottesville, VA 22908 0708, USA
    J Clin Gastroenterol 44:180-5. 2010
    ..pylori-negative subjects...
  6. ncbi request reprint Chairmen's summary: dichotomies and directions in acid-related disorders
    D A Peura
    University of Virginia, Health Sciences Center, Charlottesville, VA, USA
    Aliment Pharmacol Ther 19:77-80. 2004
    ..In all these gastrointestinal disorders, proton pump inhibitor therapy has become the common thread either as a diagnostic tool or an effective short-term or long-term management strategy...
  7. ncbi request reprint Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience
    D A Peura
    University of Virginia Health Sciences Center, Charlottesville, VA, USA
    Aliment Pharmacol Ther 30:1010-21. 2009
    ..Dexlansoprazole MR is a dual delayed release formulation of dexlansoprazole, an enantiomer of lansoprazole...
  8. ncbi request reprint Proton pump inhibitors: effective first-line treatment for management of dyspepsia
    David A Peura
    University of Virginia Health Sciences Center, Charlottesville, VA 22908 0708, USA
    Dig Dis Sci 52:983-7. 2007
    ..PPIs represent the best currently available therapy for acid-related disorders and should be considered the first-line management approach in patients with uninvestigated dyspepsia...
  9. ncbi request reprint Practical advice on eradicating Helicobacter pylori infection
    D Y Graham
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 105:137-40, 145-8. 1999
    ..Considerations for anti-H pylori treatment in a managed care environment mirror those for good medical practice in general, with special attention to stringent cost-control or outcomes-driven measures...
  10. ncbi request reprint Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis
    D Y Graham
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 105:113-6, 121-3, 127-8 passim. 1999
    ..In patients who receive treatment, confirmation of cure is important for preventing further morbidity and reducing risk of transmission of infection...
  11. ncbi request reprint Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications
    David A Peura
    Department of Gastroenterology and Hepatology, University of Virginia, Health Sciences Center, Charlottesville, Virginia 22908 0708, USA
    Am J Med 117:63S-71S. 2004
    ....
  12. ncbi request reprint Control of gastric acid secretion in health and disease
    Mitchell L Schubert
    Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University s Medical College of Virginia, McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA
    Gastroenterology 134:1842-60. 2008
    ..We review the physiology and pathophysiology of acid secretion as well as evidence regarding its inhibition in the management of acid-related clinical conditions...
  13. ncbi request reprint Helicobacter pylori infection and related gastrointestinal diseases
    Diklar Makola
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA
    J Clin Gastroenterol 41:548-58. 2007
    ....
  14. pmc The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole
    D A Peura
    University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    Aliment Pharmacol Ther 37:810-8. 2013
    ..Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting...
  15. ncbi request reprint Prevalence of gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication
    Z Lin
    Department of Medicine, University of Kansas Medical Center, Kansas City 66160-7350, USA
    Dig Dis Sci 46:739-45. 2001
    ..pylori infection. The normalization of gastric myoelectrical activity may be one explanation for the significant symptom improvement in this subset of the dyspepsia population after H. pylori eradication...
  16. ncbi request reprint Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease
    D A Peura
    Department of Gastroenterology and Hepatology, University of Virginia Health Sciences Center, Charlottesville, VA, USA
    Aliment Pharmacol Ther 38:1303-11. 2013
    ..Treatment with proton pump inhibitors (PPI) effectively decreases heartburn symptoms, but their effects on symptomatic regurgitation are less clear...
  17. ncbi request reprint Scope and consequences of peptic ulcer disease. How important is asymptomatic Helicobacter pylori infection?
    D Y Graham
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 105:100-2, 105-8, 110. 1999
    ..Elimination of the infection results in healing of gastritis and cure of peptic ulcer disease...
  18. ncbi request reprint The translation of Helicobacter pylori basic research to patient care
    Peter B Ernst
    Digestive Health Center of Excellence, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia 22908 0708, USA
    Gastroenterology 130:188-206; quiz 212-3. 2006
    ..This review summarizes important findings emanating from basic research primarily related to the immunopathogenesis of H pylori that have advanced the practice of medicine or our understanding of gastroduodenal disease...
  19. pmc Balancing the gastrointestinal benefits and risks of nonselective NSAIDs
    David A Peura
    University of Virginia Health System, Charlottesville, Virginia, USA
    Arthritis Res Ther 7:S7-13. 2005
    ..This review focuses on the gastrointestinal effects of aspirin, acetaminophen, and other nonselective NSAIDs, and discusses those factors that are associated with increased risk for adverse gastrointestinal events in certain individuals...
  20. ncbi request reprint Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors
    David A Peura
    Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville 22908, USA
    Cleve Clin J Med 69:SI31-9. 2002
    ..Selective COX-2 inhibitors (coxibs) provide effective treatment of pain and inflammation while reducing risk of gastropathy...
  21. ncbi request reprint Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials
    David A Peura
    University of Virginia, Charlottesville, Virginia, USA
    Am J Med 116:740-8. 2004
    ..This study was designed to compare the efficacy of lansoprazole with placebo in relieving upper abdominal discomfort in patients with functional dyspepsia...
  22. ncbi request reprint Helicobacter pylori-Associated Diseases
    Michael K Sanders
    Division of Gastroenterology and Hepatology, University of Virginia Health Systems, PO Box 800708, Charlottesville, VA 22908 0708, USA
    Curr Gastroenterol Rep 4:448-54. 2002
    ..pylori in these conditions. A review of the recent literature regarding H. pylori-associated diseases is presented along with recommendations for diagnosis and treatment of H. pylori infection...
  23. ncbi request reprint The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis
    J W Freston
    Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
    Aliment Pharmacol Ther 29:1249-60. 2009
    ..The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials...
  24. ncbi request reprint H. pylori: scientific basis to patient cure
    David A Peura
    University of Virginia, USA
    Rev Gastroenterol Mex 71:31-3. 2006
  25. ncbi request reprint Meshed capillary vessels found on narrow-band imaging without optical magnification effectively identifies colorectal neoplasia: a North American validation of the Japanese experience
    Zachary H Henry
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
    Gastrointest Endosc 72:118-26. 2010
    ..However, the efficacy of NBI to identify an MC pattern without optical magnification has not been determined...
  26. ncbi request reprint Heartburn: issues in patient management. A roundtable discussion
    Goutham Rao
    University of Pittsburgh School of Medicine, PA, USA
    J Fam Pract 54:s1-6. 2005
  27. ncbi request reprint Mandate to modify a medicinal mantra: maybe not yet?
    David A Peura
    Gastroenterology 124:842-4. 2003
  28. ncbi request reprint Serious gastrointestinal events from low dose analgesic use
    David A Peura
    J Rheumatol 31:1009-10; author reply 1010-1. 2004